Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

AGM Results

3 Jul 2015 09:24

RNS Number : 1152S
Electrical Geodesics, Inc
03 July 2015
 



Electrical Geodesics, Inc.

 

AGM Results

 

 

EUGENE, OREGON, US, 3 July 2015 - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, today announces that the resolutions set out in the Company's Notice of Annual General Meeting (the "Meeting") issued to stockholders on 5 June 2015 were passed by stockholders at the Meeting held in Eugene at 9.30 PST yesterday. The Annual Report and Accounts for the year ended 31 December 2014 were also received by the meeting.

 

 

Voting Results

 

Proxy and actual voting results in respect of the Ordinary Resolutions put to the meeting are shown below.

 

1.a

6,831,112

16,635,414

23,466,526

85.3%

1,499,999

5.4%

0

1.b

6,831,112

16,635,414

23,466,526

85.3%

1,499,999

5.4%

0

1.c

6,831,112

16,635,414

23,466,526

85.3%

1,499,999

5.4%

0

1.d

6,831,112

16,635,414

23,466,526

85.3%

1,499,999

5.4%

0

1.e

6,831,112

16,635,414

23,466,526

85.3%

1,499,999

5.4%

0

 

 

Ordinary Resolutions

1.a To reappoint Don Tucker as a director

1.b To reappoint Ann Bunnenberg as a director

1.c To reappoint Christine Soden as a director

1.d To reappoint John Brown as a director

1.e To reappoint Raymond Englander as a director

 

 

Copies of all resolutions and all documents referred to above are available on the Company's website at www.egi.com.

 

 

For more information contact:

 

EGI

US: Ann Bunnenberg

+1 541 687 7962

Peel Hunt LLP (NOMAD and Broker)

+44 (0) 20 7418 8900

James Steel, Clare Terlouw

 

FTI Consulting (PR Advisors)

+44 (0) 20 3727 1000

Simon Conway, Mo Noonan

 

Notes to Editors

 

Electrical Geodesics, Inc. in Summary

 

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic and neuromodulation products used to monitor, interpret and modulate brain activity, based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

 

EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalise on the Company's unique Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

 

See our website www.egi.com

 

 

Glossary

 

EEG

Electroencephalography

EMG

Electromyography

dEEG

Dense array EEG

MRI

Magnetic resonance imaging

fMRI

Functional MRI

PET

Positron emission tomography

MEG

Magneto encephalography

NIRS

Near-infra-red spectroscopy

TES

Trans-cranial electrical stimulation

TMS

Trans-cranial magnetic stimulation

 

In April 2013 EGI commenced trading on the London Stock Exchange AIM market under the symbol EGI.L. See www.egi.com for more information on the Company.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUOUWRVOABRRR

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.